INTRODUCTION AND OBJECTIVES:
Recently we demonstrated that the activated PI3K-Akt-mTOR signaling pathway induced by androgen deprivation therapy or docetaxel explains at least in part the aggressiveness in CRPC. Inhibitors of PI3K-Akt-mTOR signaling pathway have potential as next generation anti-CRPC drug. However, there have been little reports that monotherapy with a PI3K-Akt-mTOR signaling inhibitor was effective to CRPC. PIM1 is a kinase which induces expression of receptor tyrosine kinases and it has been reported to contribute Akt inhibitor resistance in lymphoma. We investigated the anti-tumor effect of PIM1 inhibitor for CRPC.
METHODS: Two cell lines were used: LNCaP, a androgendependent PCa cell line with PTEN deficiency; and C4-2AT6, a castration-resistant prostate cancer cell line with PTEN deficiency and elevated Akt signaling pathways. We investigated the therapeutic efficacy of PIM1 inhibitor; AZD1208 and PI3K/mTOR dual inhibitor; BEZ235.
RESULTS: We compared the cytotoxic effect of docetaxel (DTX) on LNCaP and C4-2AT6 cells by cell viability assay. In LNCaP and C4-2AT6 cells, the relative cell viability treated with 1nM DTX was 68.8 % AE 0.1 % and 87.5% AE 1.9 %, respectively. These results indicated that C4-2AT6 cells showed significantly higher resistance to DTX than LNCaP cells. Next we examined the cytotoxic effect of BEZ235 on LNCaP and C4-2AT6 cells by cell viability assay. In LNCaP and C4-2AT6 cells, the relative cell viability treated with 10nM BEZ235 was 90.2% AE 0.7 % and 89.9% AE 2.3 %, respectively. Western blotting showed increased expression of PIM1 and EGFR in BEZ235 treated cells. These results indicated that PI3K/mTOR inhibitor induced EGFR expression through PIM1 up-regulation. We evaluated the cytotoxic effect of AZD1208 on LNCaP and C4-2AT6. The relative cell viability was 67.9 AE 1.0 % and 67.5 AE 3.1 % with 10mM AZD1208, respectively. AZD1208 significantly inhibited cell proliferation of LNCaP and C4-2AT6. In addition, we examined synergic effect of AZD1208 and DTX/ BEZ235. The relative cell viability treated with 10mM AZD1208 and 1nM DTX was 63.8 AE 1.1 % and 48.0 AE 0.6 %. The relative cell viability treated with 10mM AZD1208 and BEZ235 was 55.9 AE 1.6 % and 46.9 AE 1.5 %. We found AZD1208 also had synergic effect with DTX and BEZ235 (Figure) .
CONCLUSIONS: PIM1 inhibition can overcome the drug resistant mechanism induced by targeting PI3K/Akt/mTOR pathways in docetaxel resistant CRPC. 
MP83-03 NOVEL SELECTIVE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITORS EFFECTIVELY IMPAIR CASTRATION RESISTANT PROSTATE CANCER GROWTH
TOSHIKI ETANI*, Taku Naiki, Nagoya, Japan; Takayoshi Suzuki, Kyoto, Japan; Takashi Nagai, Keitaro Iida, Ryosuke Ando, Noriyasu Kawai, Keiichi Tozawa, Tohru Mogami, Takahiro Yasui, Nagoya, Japan INTRODUCTION AND OBJECTIVES: Lysine-specific demethylase 1 (LSD1), the first identified histone demethylase, is a novel target for prostate cancer therapy. Herein we examined the anticancer effects of NCL1 and NCD38, the selective inhibitors of LSD1 that were first discovered at our university.
METHODS: Various tests using LNCaP (a hormone-sensitive prostate cancer cell line) and PCai1 (a castration-resistant prostate cancer [CRPC] cell line established in our institute) cells were used to confirm the anticancer effects of NCL1 and NCD38. Cell viability was assessed by performing a WST assay in the presence of NCL1, NCD38, or a standard vehicle (control). Chromatin immunoprecipitation (ChIP) and PCR were used to confirm the methylation status. For autophagy analysis, LNCaP and PCai1 cells were incubated with or without CQ in the presence or absence of NCL1. Subsequently, transmission electron microscopy (TEM), fluorescent immunocytochemistry, and WST assay were performed with the treated and nontreated cells. A combination index analysis was performed to assess the effects of NCL1 and CQ. Lastly, the effect on xenograft tumors in CRPC mice models was measured by subcutaneously injecting castrated nude mice with PCai1 cells. Mice were injected intraperitoneally with NCL1, NCD38, CQ, or the vehicle, and subsequent growth was recorded.
RESULTS: WST assay revealed a reduction in the number of viable cells after NCL1 and NCD38 treatment. ChIP showed NCL1induced H3K9me2 accumulation at the ELK4 and KLK2 promoters, whereas a dose-dependent induction of apoptosis by NCL1 was noted by flow cytometry. Autophagosomes were observed in LNCaP cells treated with NCL1. The expression level of LC3-II was significantly increased in cells treated with NCL1 and CQ. Furthermore, the combination of NCL1 and CQ significantly decreased cell growth in vitro, but had no synergistic effect in vivo. Xenograft tumor volume was reduced in the NCL1 and NCD38-treated mice when compared with the controls; no adverse effects were observed. CONCLUSIONS: Castration resistant prostate cancer growth was effectively suppressed with NCL1 and NCD38 both in vitro and in vivo, without any adverse events, via regulation of apoptosis and e1106 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
